Viewing a single comment thread. View all comments

watabadidea t1_j5yvpph wrote

Reply to comment by dariznelli in The bivalent mRNA boosters from Pfizer-BioNTech and Moderna were 48% effective against symptomatic infection from the predominant omicron subvariant (XBB/XBB.1.5) in persons aged 18-49 years according to early data published by the CDC by shiruken

I know, which is why I said "similar" and not "exact." In the yearly booster approach to COVID, the expected process would be:

  • Guess the most relevant/prevalent lineage(s) you want to protect the populace against over the next year
  • Develop a vaccine that specifically targets that lineage(s)
  • Recommend that people get one of these targeted vaccinations on an annual basis, with roll-out, messaging, and timing recommendations geared towards the period of the year where COVID infections are expected to be most prevalent

That program sounds pretty "similar" to what we have with flu shots, no?

1